THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.23] ID: TIP-MED-000455 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Trihexyphenidyl (Benzhexol) Hydrochloride

Active Ingredient / Scientific Identity: Trihexyphenidyl • Class: Centrally Acting Antimuscarinic (M1) Anticholinergic for Drug-Induced Extrapyramidal Symptoms (Schedule H | NLEM 2022)

⚖️ Compare Profile
Generic / Entity NameTrihexyphenidyl (Benzhexol) Hydrochloride ([11.23])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassCentrally Acting Antimuscarinic (M1) Anticholinergic for Drug-Induced Extrapyramidal Sympt
Available Dosage FormsStandard hospital formulary strengths
Regulatory ClassificationNon-Schedule / OTC Pharmacist-Assisted Counselling
Key Warning & Review DateHigh-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC Pharmacist-Assisted Counselling🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Trihexyphenidyl (Benzhexol) Hydrochloride (TIP-MED-000455, Reference Code [11.23]) is classified under Neurology Medicines as a Centrally Acting Antimuscarinic (M1) Anticholinergic for Drug-Induced Extrapyramidal Symptoms (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC Pharmacist-Assisted Counselling.

Verified Indian Market Examples / Compendial Status:
Representative Indian Formulations (for identification only): Pacitane (Pfizer), Parkin (Micro Labs), Bexol (Intas), Tryphen | Strengths: Tablets: 2 mg (often co-prescribed or formulated in psychiatric FDCs with Risperidone or Haloperidol — e.g., Sizodon Plus, Risdone Plus)
Representative Indian Formulations (for identification only): Pacitane (Pfizer), Parkin (Micro Labs), Bexol (Intas), Tryphen | Strengths: Tablets: 2 mg (often co-prescribed or formulated in psychiatric FDCs with Risperidone or Haloperidol — e.g., Sizodon Plus, Risdone Plus)
Dosage Forms & Available Strengths:
Standard hospital formulary strengths
Routes: Intravenous / Parenteral / Oral

3. Mechanism of Action & Pharmacodynamics

Established pharmacological class action (Centrally Acting Antimuscarinic (M1) Anticholinergic for Drug-Induced Extrapyramidal Symptoms (Schedule H | NLEM 2022)): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Treatment of acute and chronic Drug-Induced Extrapyramidal Symptoms (EPS: acute dystonia, parkinsonian rigidity, resting tremor — NOT tardive dyskinesia or akathisia!) caused by D2-blocking antipsychotics (Haloperidol, Risperidone).

4. Therapeutic Indications & Evidence-Supported Uses

  • Treatment of acute and chronic Drug-Induced Extrapyramidal Symptoms (EPS: acute dystonia, parkinsonian rigidity, resting tremor — NOT tardive dyskinesia or akathisia!) caused by D2-blocking antipsychotics (Haloperidol, Risperidone)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Start 1 mg PO OD, titrate gradually to 2 mg PO BD–TDS (Typical maintenance 2–6 mg/day; Max 10–15 mg/day in severe dystonia) (Duration: Re-evaluate need every 3 months in antipsychotic-treated patients (many patients do NOT need lifelong prophylactic Pacitane once antipsychotic dose is stabilised!);)

Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified) | Food & Meal Timing: Take WITH or immediately after meals (reduces GI upset and dry mouth) | Best Time of Day: Morning & Afternoon/Evening with meals (Avoid late night dose if it causes restlessness/delirium)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Metabolism & Biotransformation:
Renal & Hepatic: Use lowest dose with caution
Elimination & Renal Adjustment:
Renal & Hepatic: Use lowest dose with caution
Hepatic Impairment Considerations:
Renal & Hepatic: Use lowest dose with caution

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CONTRAINDICATED in narrow-angle glaucoma, Tardive Dyskinesia (Trihexyphenidyl WORSENS choreoathetoid tongue/lip movements of tardive dyskinesia!), dementia / Alzheimer's disease (directly antagonises Donepezil/Rivastigmine and causes acute delirium!), obstructive BPH urinary retention, paralytic ileus, myasthenia gravis, and megacolon

Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Dry mouth (xerostomia), blurred near vision (cycloplegia/mydriasis), constipation, urinary hesitancy/retention, sinus tachycardia, decreased sweating (anhidrosis), confusion/memory impairment, euphoria (potential for recreational anticholinergic abuse!)
Serious / Dose-Limiting Adverse Effects:
  • Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • DIRECT PHARMACODYNAMIC CLASH WITH DONEPEZIL / RIVASTIGMINE / GALANTAMINE: Trihexyphenidyl blocks central M1 muscarinic receptors while Cholinesterase Inhibitors increase acetylcholine — co-prescribing both cancels out both drugs and precipitates cognitive decline! Additive severe Anticholinergic Bur

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.

Pharmacist Patient Counselling Points:

  • THREE VITAL COUNTER RULES: (1) Take Pacitane/Parkin after meals and stay cool and well-hydrated in summer (it reduces sweating and can cause heat stroke)
  • (2) Never give to an elderly patient with memory loss/dementia or someone taking Donepezil

Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Tablets: 2 mg (often co-prescribed or formulated in psychiatric FDCs with Risperidone or Haloperidol — e.g., Sizodon Plus, Risdone Plus)). Missed-Dose Rule: Take with next meal if remembered; never stop abruptly (rebound cholinergic cholinergic rebound & parkinsonian stiffness)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.